-
1
Antibody-drug conjugates (ADCs) target tumor-associated antigens, offering potential for biomarker-guided prostate cancer treatment.
-
2
Challenges in ADC application include antigen diversity, resistance, linker integrity, and adverse effects, impacting clinical efficacy.
-
3
The study identified 118 clinical trials for ADCs in prostate cancer, with a significant focus on early-phase exploratory studies.
-
4
TOP1-based payloads dominate ADC trials, while target selection has expanded to include 35 different antigens, addressing tumor heterogeneity.
-
5
ADC trials are primarily sponsored by small biopharmaceutical firms, with a geographic concentration in North America and Asia.
